RHYTHM PHARMACEUTICALS, INC.

Rhythm Pharmaceuticals, Inc. (NASDAQ: RRHI) is a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with rare neuroendocrine diseases. The company focuses on developing melanocortin-4 receptor (MC4R) agonists as precision medicines designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. www.rhythmtx.com

The company's lead asset, IMCIVREE (setmelanotide), is the first-ever therapy approved and marketed in the United States, European Union, United Kingdom, Canada, and several other countries for certain rare MC4R pathway diseases, including Bardet-Biedl syndrome and obesity caused by POMC, PCSK1, or LEPR deficiency. IMCIVREE is approved for use in patients aged two years and older. The company is advancing two earlier-stage investigational MC4R agonists: bivamelagon, an oral small molecule, and RM-718, designed for weekly subcutaneous administration. Both candidates are engineered to exhibit high selectivity for MC4R while functionally sparing MC1R, avoiding hyperpigmentation associated with earlier therapies.

Rhythm's clinical development pipeline addresses three key disease areas. The company is preparing for global commercialization of setmelanotide for acquired hypothalamic obesity beginning in 2026, pending regulatory approval. The company is also evaluating setmelanotide in congenital hypothalamic obesity and Prader-Willi syndrome, with preliminary Phase 2 data showing encouraging results in PWS. Additionally, the company is advancing its Phase 3 EMANATE trial, comprised of four independent substudies evaluating setmelanotide in genetically caused MC4R pathway diseases, with topline data expected in March 2026.

The company leverages what it believes is the largest known DNA database focused on obesity, containing approximately 120,000 sequencing samples as of December 31, 2025, to improve understanding, diagnosis, and care of patients with severe obesity due to MC4R pathway variants. As of February 1, 2026, Rhythm employed 414 people, including 126 employees in eleven countries outside North America. The company has generated approximately $422.5 million from product sales to date and maintains a global foundation with IMCIVREE achieving regulatory approvals and market access in more than twenty-five countries.